Published in Gene Therapy Weekly, September 13th, 1999
J. Lukas and colleagues from the Danish Cancer Society, Denmark, examined p16(INK4a) and pRb genes for their role in oncogenesis. Their results were reported in the journal Oncogene ("p16(INK4a), But Not Constitutively Active pRb, Can Impose a Sustained G1 Arrest: Molecular Mechanisms and Implications for Oncogenesis," Oncogene, July 8, 1999;18(27):3930-3935).
"p16(ink4a) and pRb, two components of a key G1/S regulatory pathway, and tumor suppressors commonly targeted in oncogenesis, are among the candidates for gene therapy of cancer," wrote Lukas et al. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.